Published in final edited form as:

J Nat Prod. 2012 April 27; 75(4): 661–668. doi:10.1021/np2008957.

Configurational Reassignment and Improved Preparation of the Competitive IL-6 Receptor Antagonist 20*R*,21*R*-Epoxyresibufogenin-3-formate

Terrence L. Boos[†], Kejun Cheng[†], Elisabeth Greiner^{†,‡}, Jeffrey R. Deschamps[§], Arthur E. Jacobson[†], and Kenner C. Rice^{†,*}

[†]Drug Design and Synthesis Section, Chemical Biology Research Branch, NIDA and NIAAA, National Institutes of Health, Department of Health and Human Services, 5625 Fishers Lane, Room 4N03, Bethesda, MD 20892-9415, USA

[§]Center for Biomolecular Science and Engineering, NRL, Washington DC 20375, USA

Abstract

20*R*,21*R*-Epoxyresibufogenin-3-formate (**1**) and 20*S*,21*S*-epoxyresibufogenin-3-formate (**2**) were synthesized from commercial resibufogenin (**3**) using known procedures. The major product (**1**) was dextrorotatory, as was the major product from the reported synthesis of epoxyresibufogenin-3-formate; however, the literature (+)-compound was assigned the 20*S*,21*S*-configuration based on NMR data. We have now unequivocally determined, using single-crystal X-ray structure analyses of the major and minor products of the synthesis and of their derivatives, that the major product from the synthesis was (+)-20*R*,21*R*-epoxyresibufogenin-3-formate (**1**). Our minor synthetic product was determined to have the (-)-20*S*,21*S*-configuration (**2**). The (+)-20*R*,21*R*-compound **1** has been found to have high affinity for the IL-6 receptor and to act as an IL-6 antagonist. A greatly improved synthesis of **1** was achieved through oxidation of preformed resibufogenin-3-formate. This has enabled us to prepare, from the very expensive commercial resibufogenin, considerably larger quantities of **1**, the only known non-peptide small molecule IL-6 antagonist.

The only known non-peptide small molecule antagonist for the interleukin-6 receptor (IL-6R) that has been found to be selective and to have high affinity, an epoxyresibufogenin-3-formate, has been pharmacologically examined in a number of assay systems.^{1–6} In order to obtain a relatively large quantity of the compound for our exploration of the IL-6 receptor system we resynthesized 20*R*,21*R*- and 20*S*,21*S*-epoxyresibufogenin-3-formate (**1** and **2**, respectively, Scheme 1) using the literature¹ procedure and determined, from X-ray crystallographic analyses, that the formerly reported configurational assignments were reversed. New pharmacological assays were in agreement with our reassignment of their configuration. Future SAR studies based on these IL-6 antagonists will, of course, be dependent on their correct configuration.

Both the sympathetic and central nervous (CNS) systems play important roles in the immune response to tissue damage and infection. Involved in that response are cytokines, cell-signaling small proteins secreted by glial cells; one of them, IL-6, is an essential proinflammatory cytokine.^{7, 8} Many abnormal conditions and diseases are related to the overproduction and dysregulation of proinflammatory cytokines. The pathogenesis of CNS

*Corresponding author. Tel.: 301-496-1856; fax: 301-402-0589; kr21f@nih.gov.

‡Present address: df-mp, Fünf Höfe, Theatinerstraße 16, 80333 Munich, Germany

inflammation in, for example, rheumatoid arthritis⁹ and osteoporosis, has been linked to IL-6 dysregulation.⁶ Chronic low-grade inflammation has been directly linked to an increased risk of morbidity and mortality.¹⁰ Thus, modulation of cytokine function may be of interest for the treatment of conditions associated with a considerable number of diseases. A small molecule non-peptide antagonist of the IL-6 mediated response can be an invaluable research tool with potentially great therapeutic significance.

Kaneda *et al.*¹¹ found that the main constituent of a crude drug, Ch'an Su (toad cake, a folk medicine used in China and other Asian countries), was resibufogenin (**3**, Scheme 1). This medicine was prepared from skin secretions of toads of the *Bufo* genus (venenum Bufonis), and it was reported to be cardiotoxic with a high mortality rate when used in the United States.¹² Epoxyresibufogenin was a minor constituent of the drug. More recently, Kamano *et al.* also isolated the more potent bufogenin compounds, 20*R*,21*R*- and 20*S*,21*S*-epoxyresibufogenin (**4** and **5**, respectively, Scheme 1) from Ch'an Su.¹ They also synthesized 20*R*,21*R*- and 20*S*,21*S*-epoxyresibufogenin-3-formate from resibufogenin (**3**), and they obtained a major (dextrorotatory) and a minor (levorotatory) product. Hyashi *et al.*, found⁴ that the dextrorotatory 20,21-epoxyresibufogenin-3-formate that they used (and that they believed to be the 20*S*,21*S*-epimeric epoxide) was an interleukin-6 receptor antagonist. Enomoto *et al.*, also noted² that the 20*S*,21*S*-compound from Ch'an Su was a competitive antagonist of IL-6, and examined its SAR.

In the synthetic procedure of Kamano *et al.*,¹ the natural product resibufogenin (**3**) was oxidized to give a dextrorotatory major product that was noted¹ to have the same spectral data as the natural epoxide **4**, and a minor product, a levorotatory epoxide **5** (Scheme 1). Using 2D NMR and NOESY correlations, they assigned the 20*S* configuration to the (+)-epoxide (the major product, **4**), and the 20*R* configuration to the (–)-epoxide (the minor product, **5**). Compounds **4** and **5** are the precursors to the pharmacologically active formates **1** and **2**, respectively (Scheme 1).

We repeated the synthesis of Kamano *et al.*,¹ using resibufogenin (**3**, Scheme 1) that we obtained commercially from Indofine Chemical Co., Inc. (NJ), and obtained a major (**4**) and minor (**5**) product. Our compound **4** had a double melting point; double and high melting point compounds in the bufalin series have been reported.¹³ The published ¹H and ¹³C NMR spectra¹ for the major and minor products were, in general, similar to those that we obtained. A comparison of selected chemical shifts from ¹H NMR and comparisons of ¹³C NMR and IR spectra are shown in Tables 1–3. The overall yields that we obtained were consistent with the published procedure, and we initially assumed that **1**, the major diastereomeric product, had the 20*S* configuration. Our high resolution mass spectrometric analysis supported the preparation of **1** and **2**.

However, our specific rotations and melting points were different from those that have been reported. The reported specific rotations for the major (dextrorotatory) and minor (levorotatory) product of Kamano *et al.*,¹ were $[\alpha]^{20}_{\text{D}} +17.2$ (*c* 0.1, CHCl₃) and $[\alpha]^{20}_{\text{D}} -11.5$ (*c* 0.1, CHCl₃), respectively. The optical rotations of the major (dextrorotatory) and minor (levorotatory) product that we obtained were $[\alpha]^{20}_{\text{D}} +64$ (*c* 0.1, CHCl₃) and $[\alpha]^{20}_{\text{D}} -32$ (*c* 0.1, CHCl₃), respectively. Our observed melting points for the major (dextrorotatory) and minor (levorotatory) products were 159–160 °C (lit.¹ mp 180–182 °C) and 142–143 °C (lit.¹ mp 147–150 °C). Because of these differences, we decided to establish the structure of our compounds by single crystal X-ray diffraction studies (Figure 1). Among the non-bromine containing compounds **1**, **2** and **6** (Figures 1 and 2) only compound **6** was characterized using likelihood methods developed by Hooft *et al.*,¹⁴ as implemented in PLATON.¹⁵ CuKα data was used for compounds **4** and **6** (the polymorph of **6** was collected with MoKα radiation). These methods indicated that the absolute stereo-structure had been

correctly assigned. The probability that structure **6** is inverted (as calculated using this method) is smaller than 1×10^{-26} .

When the results of the X-ray analysis contradicted a previously published result we felt it prudent to be certain of our result and took the extra step of preparing and analyzing the heavy-atom containing compound **8**. This allowed both confirmation of the result and a direct comparison of the methods of Hooft¹⁴ and Flack.¹⁶ This also seemed important as the method of Hooft is relatively new and has not been widely applied. Compound **8** is the *p*-bromobenzoate ester of 20*R*,21*R*-epoxyresibufogenin (**4**). The crystal structure of **8** was analyzed using the method of Hooft *et al.*,¹⁴ and the more widely accepted method of Flack.¹⁶ The two methods were in agreement on the absolute configuration. The Flack parameter for the bromobenzoate ester **8** was 0.007(3) and the Hooft method¹⁴ indicated that the probability that the configuration was wrong was 0.1×10^{-115} . All of the structural features of our compounds were consistent with the literature except for the configuration of the C-20, C-21 oxirane moiety. The configuration at C-20 and C-21 was found to be opposite to the previously reported 20*S*, 21*S*.¹

In the ¹H NMR spectra, the (+)-diastereomer (**1**), that we determined to have the 20*R*,21*R* configuration by X-ray analyses, showed a doublet for H-22 at δ 7.93 for the C-20,C-21 epoxide (in Kamano *et al.*,¹ this was associated with the compound assigned the 20*S*,21*S*(+) configuration), and our 20*S*,21*S*(-)-diastereomer (**2**) showed a broad singlet for H-22 at δ 7.69 for the C-20,C-21 epoxide (in Kamano *et al.*,¹ that was associated with the compound that they assigned the 20*R*,21*R*(+) configuration). The optical rotations of the samples obtained subsequent to the X-ray crystallographic studies were re-determined and found to be as noted above. Since we were surprised to find that the configuration appeared to be misassigned or mislabeled in the Figures or Experimental section,¹ we converted 20*R*,21*R*(+)-epoxyresibufogenin **4** to the dextrorotatory 3-acetate derivative³ **6** which had not formerly been examined using single crystal X-ray diffraction studies. The results of that X-ray study (Figure 2) were in agreement with our studies of the formate compounds. We concluded that the major product of the synthesis was 20*R*,21*R*-epoxyresibufogenin (**4**), and that **1**, derived from **4**, must be (+)-20*R*,21*R*-epoxyresibufogenin-3-formate. (-)-20*S*,21*S*-Epoxyresibufogenin-3-formate (**2**) was derived from the minor product, 20*S*,21*S*-epoxyresibufogenin (**5**).

The interaction of the formates **1** and **2** with the IL-6 receptor were examined using different assays than those noted in the literature,^{1, 2, 4} and compound **1** (Scheme 1), with the reassigned (+)-20*R* configuration, was determined to be a pharmacologically active diastereomer; it was found to reduce pancreatitis-induced pain by peripheral mechanisms.⁶ In another pharmacological assay, suppression of IL-6-induced α 1-antichymotrypsin mRNA expression, 20*R*,21*R*-epoxyresibufogenin-3-formate **1** was found to specifically inhibit an IL-6-mediated signaling pathway; the 20*S*,21*S*-epoxyresibufogenin-3-formate **2** had a lesser effect on that pathway.⁵

We then reexamined the synthesis of (+)-20*R*,21*R*-epoxyresibufogenin-3-formate (**1**, Scheme 1) in order to obtain larger quantities for pharmacological studies. An improved path to the compound was important because the commercially available starting material, resibufogenin, was very expensive. We found that rather than an initial oxidation of resibufogenin (**3**) followed by formylation as shown in Scheme 1, it was much better if the formylation preceded the oxidation. As shown in Scheme 1, acetic formic anhydride in pyridine at low temperatures gave the formylated product **7**¹⁷ in 93% yield. Two methods of oxidation of the resibufogenin 3-formate (**7**)¹⁷ were successfully implemented. In the first method a solution of dimethyldioxirane in acetone was used to oxidize the formyl compound **7** at room temperature. After 2 days, a 71% yield of the target 20*R*,21*R*-

epoxyresibufogenin-3-formate (**1**) was obtained. In the second method, an acetonitrile solution of resibufogenin 3-formate was added to an aqueous disodium-EDTA solution. The cold mixture was reacted with Oxone,²¹ and the reaction was complete in 1 h to give a 56% yield of **1**. The overall yield of **1** from **3** ranged from 65% (method 1) to 52% (method 2). Either method was a significant improvement over the procedure in Scheme 1 (ca. 20% yield over 2 steps), and the new synthesis was used to prepare a sufficient quantity of **1** for further pharmacological work.

Experimental Section

General Experimental Procedures

For Scheme 1: All melting points were determined on a Thomas-Hoover melting point apparatus and are uncorrected. The IR data were obtained on a Perkin-Elmer Spectrum One FTIR instrument. The ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra were recorded at room temperature on a Varian XL-300 instrument with CDCl₃ as solvent, δ values in ppm (TMS as internal standard), *J* (Hz) assignments of ¹H resonance coupling. HRMS were obtained on a Waters/Micromass LCT ESI-TOF. TLC was performed on 250 mm Analtech GHLF silica gel plates using EtOAc-hexanes, 1:1, as the solvent system. Elemental analyses were performed by Atlantic Microlabs, Inc., Norcross, GA. Resibufogenin was obtained from Indofine Chemical Company, Inc. (Hillsborough, NJ).

For Scheme 2 (changes from Scheme 1): ¹H NMR (500 MHz) and ¹³C NMR (125 MHz) spectra were recorded at room temperature on a Bruker-500 instrument in CDCl₃ (unless otherwise noted). HRMS were obtained on a Waters/Premier LCT ESI-TOF. Flash column chromatography was performed with Bodman silica gel LC 60 A. Elemental analyses were performed by Micro-Analysis, Inc., Wilmington, DE.

Resibufogenin (3)—Commercial resibufogenin was an off-white crystalline solid, mp 150–152 °C (lit.¹⁸ mp 108–120 °C, 162–166 °C); [α]_D²⁰ –6 (*c* 0.1, CHCl₃) (lit.¹⁹ [α]_D¹⁶ –5.4 (*c* 2.3, CHCl₃)); ¹H NMR (CDCl₃, 500 MHz) δ 7.80 (1H, dd, *J* = 2.8, 12.8 Hz), 7.25 (1H, s), 6.24 (1H, d, *J* = 12.8 Hz), 4.14 (1H, t, *J* = 2.7 Hz), 3.53 (1H, s), 2.52–2.33 (2H, m), 2.18 (1H, s), 2.06–1.16 (16H, m), 0.99 (3H, s), 0.78 (3H, s); ¹³C NMR (CDCl₃, 125 MHz) δ 149.5, 147.0, 122.2, 115.2, 74.7, 66.7, 59.8, 47.7, 45.2, 39.3, 39.2, 35.9, 35.4, 33.5, 33.2, 32.3, 29.5, 27.8, 25.7, 23.7, 21.0, 20.7, 16.8; HRESIMS *m/z* 385.2371 (calcd for C₂₄H₃₃O₄, 385.2379).

20*R*,21*R*-Epoxyresibufogenin (**4**) and 20*S*,21*S*-Epoxyresibufogenin (**5**)—

Resibufogenin **3** (0.31 g, 0.80 mmol) and tris(acetylacetonato)iron(III) (2.5 g, 7.1 mmol) were combined in acetonitrile (250 mL). To the solution was added 30% H₂O₂ (18 mL) dropwise at 0 °C. The mixture was filtered and poured into ice-water (3 × 150 mL). The solution was extracted with CH₂Cl₂. The combined extracts were washed with 5% aq sodium thiosulfate, NaHCO₃, and H₂O. The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure. The diastereomers were separated by column chromatography employing EtOAc-hexanes (1:1) as the solvent system. The major (dextrorotatory) product (**4**) was obtained in yields ranging from 24–31% (lit.¹ 24%), as a white crystalline solid, (*R*_f = 0.35): mp 123–124 °C and 220–222 °C (lit.¹ mp 184–186 °C for the reported 20*S*,21*S*-epoxyresibufogenin); [α]_D²⁰ +46.0 (*c* 0.1, CHCl₃) (lit.¹ [α]_D¹⁸ +18.2 (*c* 0.1, CHCl₃), for the reported 20*S*,21*S*-epoxyresibufogenin); IR (KBr and solid probe), see Table 3; ¹H NMR (CDCl₃, 300 MHz) δ 7.93 (1H, dd, *J* = 10.4, 1.2 Hz, H-22), 6.04 (1H, d, *J* = 10.2 Hz, H-23), 5.30 (1H, d, *J* = 1.2 Hz, H-21), 4.13 (1H, m, H-3), 3.57 (1H, s, H-15), 2.27 (2H, m, H-16), 2.18–1.24 (19H, m), 1.02 (3H, s, H-18), 0.99 (3H, s, H-19); ¹³C NMR (CDCl₃, 300 MHz) δ 160.1, 148.1, 121.6, 84.8, 75.4, 66.9, 60.1, 56.7, 51.9, 44.3, 39.9, 39.4, 36.1, 35.7, 33.4, 29.7, 28.8, 28.0, 25.9, 23.9, 20.9, 20.8, 16.4;

HRESIMS m/z 401.2330 (calcd for $C_{24}H_{33}O_5$ 401.2328); anal. C 69.75, H 8.24, O 21.92%, calcd for $C_{24}H_{32}O_5 \cdot 0.7 H_2O$, C 69.78, H 8.15; O 22.07%.

The minor (levorotatory) product **5** was obtained in yields ranging from 16–20% (lit.¹ 13%), $R_f = 0.28$, as a white crystalline solid; mp 114–116 °C and 235–237 °C (lit.¹ mp 90–94 °C for the reported 20*R*,21*R*-epoxyresibufogenin); $[\alpha]^{20}_D -17.9$ (c 0.1, $CHCl_3$) (lit.¹ $[\alpha]^{19}_D -17.0$ (c 0.1, $CHCl_3$, for the reported 20*R*,21*R*-epoxyresibufogenin)); IR (KBr and solid probe), see Table 3; 1H NMR (300 MHz) δ 7.69 (1H, d, $J = 9.9$ Hz, H-22), 6.07 (1H, d, $J = 10.2$ Hz, H-23), 5.40 (1H, s, H-21), 4.14 (1H, s, H-3), 3.45 (1H, s, H-15), 2.18–1.25 (19H, m), 1.19 (3H, s, H-18), 1.01 (3H, s, H-19); ^{13}C NMR ($CDCl_3$, 75 MHz) δ 160.1, 149.6, 122.4, 83.1, 75.3, 66.9, 60.1, 55.7, 50.3, 45.0, 40.1, 39.4, 36.1, 35.7, 33.4, 33.2, 29.7, 28.0, 25.9, 23.9, 20.9, 20.8, 16.1; HRESIMS m/z 401.2348 (calcd for $C_{24}H_{33}O_5$ 401.2328); anal. C 69.31, H 8.16, O 21.51%, calcd for $C_{24}H_{32}O_5 \cdot 0.75 H_2O$, C 69.62, H 8.16, O 22.21%.

20*R*,21*R*-Epoxyresibufogenin 3-acetate (6)—20*R*,21*R*-epoxyresibufogenin **4** (80 mg, 0.02 mmol) and Ac_2O (2.0 mL) were combined in pyridine (4.0 mL) and stirred for 24 h at room temperature. The solution was poured into H_2O (75 mL) and extracted with CH_2Cl_2 . The combined extracts were washed with H_2O (3×75 mL) to remove the final traces of pyridine and dried over Na_2SO_4 . The solvent was removed under reduced pressure to yield a white solid which was recrystallized from acetone to give needles, 67 mg (0.02 mmol, 76%), mp 152–153 °C; $[\alpha]^{20}_D +57.3$ (c 1.0, $CHCl_3$); 1H NMR: δ 7.93 (1H, dd, $J = 10.2$ Hz, 1.1 Hz, C-22), 6.05 (1H, d, $J = 10.2$ Hz, C-23), 5.30 (1H, d, $J = 0.8$ Hz, C-21), 5.09 (1H, m, C-3), 3.58 (1H, s, C-15), 2.31–1.23 (19H, m), 1.03 (3H, s, C-18), 1.00 (3H, s, C-19); ^{13}C NMR: δ 170.8, 160.0, 148.1, 121.6, 84.7, 75.3, 70.4, 60.1, 56.7, 51.8, 44.2, 39.7, 39.5, 36.9, 35.4, 33.3, 31.1, 30.5, 30.4, 28.7, 25.7, 25.1, 23.8, 21.6, 20.8, 20.7, 16.4; HRESIMS m/z 443.2422 (calcd for $C_{26}H_{35}O_6$ 443.2434); anal. C 69.68, H 7.81, O, 22.51%, calcd for $C_{26}H_{34}O_6 \cdot 0.25 H_2O$, C 69.85, H 7.78; O 22.37%.

20*R*,21*R*-Epoxyresibufogenin 3-formate (1) from 20*R*,21*R*-Epoxyresibufogenin (4)—20*R*,21*R*-epoxyresibufogenin **4** (310 mg, 0.77 mmol) and HCO_2H (6.6 mL) were combined in pyridine (6.0 mL) and stirred for 24 h at room temperature. The solution was poured into H_2O (75 mL) and extracted with CH_2Cl_2 . The combined extracts were washed with H_2O (3×75 mL) to remove the final traces of pyridine and dried over Na_2SO_4 . The solvent was removed under reduced pressure to yield a white solid, 240 mg (72%). The residue was purified by column chromatography on silica gel, eluting with EtOAc-hexanes (1:1) as solvent system to give needles. Recrystallization from acetone gave 47 mg of a crystalline solid (0.11 mmol, 14%, $R_f = 0.69$), mp 166–167 °C (lit.¹ mp 180–182 °C for the reported “20*S*,21*S*-epoxyresibufogenin”); $[\alpha]^{20}_D +64.0$ (c 0.1, $CHCl_3$) (lit.¹ $[\alpha]^{19}_D +17.2$ (c 0.1, $CHCl_3$, for the reported “20*S*,21*S*-epoxyresibufogenin”)); IR (KBr) ν_{max} 3032, 2940, 2881, 1743, 1449, 1374, 1148, 1120, 1093, 984, 868, 838 cm^{-1} ; 1H NMR: δ 8.07 (1H, s, CO_2H), 7.93 (dd, 1H, $J = 10.3, 1.2$ Hz, H-22), 6.05 (1H, d, $J = 10.3$ Hz, H-23), 5.31 (1H, s, C-21), 5.24 (1H, s, H-3), 3.57 (1H, s, H-15), 2.31–1.23 (19H, m), 1.03 (3H, s, H-18), 1.01 (3H, s, H-19); ^{13}C NMR: see Table 2; HRDEIMS m/z 428.2203 (calcd for $C_{25}H_{32}O_6$, 428.2199); anal. C 69.39, H 7.62%, calcd for $C_{25}H_{32}O_6 \cdot 0.25 H_2O$, C 69.34, H 7.56%.

20*R*,21*R*-Epoxyresibufogenin 3-formate (1) from resibufogenin 3-formate (7).

Method A—To a solution of resibufogenin 3-formate (**7**, 206 mg, 0.50 mmol) in 6 mL of CH_2Cl_2 was added a solution of dimethyldioxirane²⁰ in acetone (4.5 mL, ~0.26 mmol) at room temperature. The progress of the reaction was followed by TLC; conversion was about 60% in 20 h. Removal of solvent gave a white crystalline solid. The solid was dissolved in CH_2Cl_2 (50 mL) and dried with anhydrous Na_2SO_4 . The drying agent was filtered and washed with CH_2Cl_2 . The solvent was removed and the residue was separated by column

chromatography on silica gel, eluting with EtOAc-hexanes 1:1 to give 151 mg (0.35 mmol) of **1** as a colorless crystalline solid (conversion: 85%, yield: 71%); mp 165–167 °C; $[\alpha]_D^{20} +62.8$ (*c* 1.0, CHCl₃).

Method B:²¹—To an acetonitrile solution (5 mL) of resibufogenin 3-formate (**7**, 206 mg, 0.50 mmol) was added an aqueous disodium-EDTA solution (2.0 mL, 0.4 mM). The resulting heterogeneous solution was cooled to 5 °C, followed by addition of trifluoroacetone (1.0 mL) *via* a pre-cooled syringe. To this solution was added a mixture of NaHCO₃ (0.65 g, 7.75 mmol) and Oxone²¹ (1.53 g, 5.0 mmol), all at once. The reaction was complete in 1 h as shown by TLC. Anhydrous Na₂SO₄ was added, followed by anhydrous CH₂Cl₂ (80 mL). The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (40% EtOAc in hexanes as eluent) to provide 121 mg (0.28 mmol) of **1** as a colorless crystalline solid (conversion: 90%, yield: 56%).

20S,21S-Epoxyresibufogenin 3-formate (2)—20S,21S-epoxyresibufogenin **5** (180 mg, 0.45 mmol) and formic acid (4.4 mL) were combined in pyridine (4.0 mL) and stirred for 24 h at room temperature. The solution was poured into H₂O (75 mL) and extracted with CH₂Cl₂. The combined extracts were washed with H₂O (3 × 75 mL) to remove the final traces of pyridine and dried over Na₂SO₄. The solvent was removed under reduced pressure to yield a white solid. The residue was purified by column chromatography on silica gel, eluting with EtOAc-hexanes (1:1) as solvent system to give a white solid. Recrystallization from acetone provided 35 mg of a crystalline solid (0.08 mmol, 18%, *R*_f = 0.71); mp 142–143 °C (lit.¹ mp 147–150 °C); $[\alpha]_D^{20} -32.0$ (*c* 0.1, CHCl₃) (lit.¹ $[\alpha]_D^{19} -11.5$ (*c* 0.1, CHCl₃); IR (KBr) $\nu_{\max}$ = 2937, 1748, 1707, 1448, 1376, 1193, 1152, 1119, 1094, 983, 880 cm⁻¹; HRFABMS *m/z* 429.2273 (calcd for C₂₅H₃₃O₆, 429.2277); ¹H NMR: δ 8.07 (1H, s, H-CO₂); 7.69 (1H, d, *J* = 9.9 Hz, H-22); 6.07 (1H, d, *J* = 9.9 Hz, H-23); 5.41 (1H, s, H-21); 5.24 (1H, s, H-3); 3.46 (1H, s, H-15); 2.18–1.23 (19H, m); 1.19 (3H, s, H-18); 1.03 (3H, s, H-19); ¹³C NMR: δ 160.9, 160.1, 149.6, 122.5, 83.1, 75.2, 70.6, 60.2, 55.7, 50.4, 45.1, 40.1, 39.7, 36.9, 35.5, 33.3, 30.6, 30.4, 28.2, 25.8, 25.2, 23.9, 20.9, 20.8, 16.1; anal. C 69.87, H 7.59, O 22.35%, calcd for C₂₅H₃₂O₆, C 70.07, H 7.53, O, 22.40%.

Resibufogenin 3-formate (7).¹⁷—To a solution of resibufogenin (**3**, 4.23 g, 0.01 mol) in dry pyridine (100 mL) was added acetic formic anhydride²² (30 mL). The mixture was left at 0–5 °C for 2 h and poured into ice water and extracted with CHCl₃. The organic layer was washed successively with 1N HCl, H₂O, saturated NaHCO₃, and H₂O, dried, and evaporated. The residue was separated by column chromatography on silica gel, eluting with EtOAc-hexanes 1:1 to give 4.20 g (0.01 mol) of **7** as colorless crystals: (93%), mp 218–220 °C; $[\alpha]_D^{20} -4.4$ (*c* 1.04, CHCl₃); ¹H NMR: δ 8.07 (1H, s), 7.78 (1H, d, *J* = 9.5 Hz), 7.24 (1H, s), 6.25 (1H, d, *J* = 10.0 Hz), 5.25 (1H, s), 3.53 (1H, s), 2.46 (1H, d, *J* = 10.0 Hz), 2.38 (1H, dd, *J* = 15.0, 10.0 Hz), 2.05–1.82 (4H, m), 1.75–1.18 (16H, m), 1.02 (3H, s), 0.88–1.0 (1H, m), 0.78 (3H, s); ¹³C NMR: δ 162.1, 160.8, 149.7, 147.1, 122.3, 115.4, 74.7, 70.6, 60.0, 47.9, 45.4, 39.6, 39.4, 36.8, 35.4, 33.7, 32.5, 30.5, 30.3, 25.6, 25.2, 23.9, 21.2, 20.7, 17.0; HRESIMS *m/z* 413.2325 (calcd for C₂₅H₃₃O₅, 413.2328; anal. C 72.89, H 7.66%, calcd for C₂₅H₃₂O₅, C 72.79, H 7.82%.

20R,21R-Epoxyresibufogenin 3-(4-bromobenzoate) (8)—To a solution of 20R, 21R-epoxyresibufogenin (**4**, 33.0 mg, 0.08 μmol) in 1.0 mL of CH₂Cl₂ was added DMAP (25.2 mg, 0.02 mmol) and *p*-bromobenzoyl chloride (36.2 mg, 0.17 mmol). The solution changed to a suspension immediately and the mixture was stirred overnight at room temperature. The mixture was separated by column chromatography on silica gel, eluting with EtOAc-hexanes (1:3) to afford colorless crystals, 36 mg (0.07 mmol, 81%), mp 177–

178 °C and 184–186 °C; $[\alpha]_D^{20} +50.7$ (c 0.4, CHCl_3). The ester was recrystallized from EtOAc-hexanes to obtain a crystal suitable for X-ray crystallography; ^1H NMR δ 7.95 (1H, dd, $J=1.0, 10.2$ Hz), 7.90 (2H, d, $J=9.0$ Hz), 7.59 (2H, d, $J=9.0$ Hz), 6.04 (1H, d, $J=10.5$ Hz), 5.34 (s-br, 1H), 5.31 (d, 1H, $J=1.0$ Hz), 4.13 (m, 1H), 3.59 (1H, s), 2.34–2.28 (2H, m), 2.05 (1H, s), 2.05–1.24 (16H, m), 1.05 (s, 3H), 1.04 (3H, s); ^{13}C NMR: δ 165.3, 160.0, 148.0, 131.8, 131.2, 130.0, 128.0, 121.6, 84.7, 75.2, 71.4, 60.0, 56.6, 51.9, 44.2, 39.7, 39.5, 37.3, 35.5, 33.4, 33.4, 30.8, 30.7, 28.7, 25.8, 25.3, 24.0, 20.8, 16.4; HRESIMS m/z 583.1708 (calcd for $\text{C}_{31}\text{H}_{36}\text{BrO}_2$, 583.1695); anal. C 63.43, H 5.98%, calcd for $\text{C}_{31}\text{H}_{35}\text{BrO}_2$, C 63.81, H 6.05%.

X-ray Crystal Structure of Compounds 1, 2, 4, 6, and 8—Single-crystal X-ray diffraction data of compounds **1**, **2**, **4**, **6**, and **8** were collected using MoK α radiation ($\lambda = 0.71073$ Å) and a Bruker APEX 2 CCD area detector except where noted. The structures were solved by direct methods and refined by full-matrix least squares on F^2 values using the programs found in the SHELXTL suite (Bruker, SHELXTL v6.10, 2000, Bruker AXS Inc., Madison, WI). Parameters refined included atomic coordinates and anisotropic thermal parameters for all non-hydrogen atoms. Hydrogen atoms on carbons were included using a riding model [coordinate shifts of C applied to H atoms] with C–H distance set at 0.96 Å. Atomic coordinates for these compounds have been deposited with the Cambridge Crystallographic Data Centre (deposition numbers for compounds **1**, **2**, **4**, **6**, **6** (polymorph), and **8** are 851340, 851341, 851342, 851343, 851344, and 851345, respectively). Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK [fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].

Compound 1—A $0.42 \times 0.23 \times 0.10$ mm³ crystal of **1** was prepared for data collection coating with high viscosity microscope oil (Paratone-N, Hampton Research). The oil-coated crystal was placed on a MicroMesh mount (MiTeGen, Ithaca, NY) and transferred immediately to the cold stream (93°K) on the diffractometer. The crystal was monoclinic in space group $P2_1$ with unit cell dimensions $a = 9.2499(12)$ Å, $b = 10.3002(13)$ Å, $c = 11.7027(15)$ Å, and $\beta = 104.951(2)^\circ$. Corrections were applied for Lorentz, polarization, and absorption effects. Data were 96.7% complete to $28.31^\circ \theta$ (approximately 0.75 Å) with an average redundancy of 2.79.

Compound 2—A $0.45 \times 0.44 \times 0.06$ mm³ crystal of **2** was prepared for data collection coating with high viscosity microscope oil (Paratone-N, Hampton Research). The oil-coated crystal was placed on a MicroMesh mount (MiTeGen, Ithaca, NY) and transferred immediately to the cold stream (93°K) on the diffractometer. The crystal was monoclinic in space group $P2_1$ with unit cell dimensions $a = 8.3511(10)$ Å, $b = 18.955(2)$ Å, $c = 14.0356(16)$ Å, and $\beta = 102.781(2)^\circ$. Corrections were applied for Lorentz, polarization, and absorption effects. Data were 99.5% complete to $26.37^\circ \theta$ (approximately 0.80 Å) with an average redundancy of 3.39.

Compound 4—A $0.632 \times 0.296 \times 0.275$ mm³ crystal of **4** was prepared for data collection coating with high viscosity microscope oil (Paratone-N, Hampton Research). The oil-coated crystal was placed on a MicroMesh mount (MiTeGen, Ithaca, NY) and transferred immediately to the cold stream (200°K) on the diffractometer and data was collected using CuK α radiation ($\lambda = 1.54178$ Å) and a Bruker Platinum-135 CCD area detector. The crystal was tetragonal in space group $P4_32_12$ with unit cell dimensions $a = b = 11.0131(3)$ Å, and $c = 34.7409(8)$ Å. Corrections were applied for Lorentz, polarization, and absorption effects. Data were 99.7% complete to $68.45^\circ \theta$ (approximately 0.83 Å) with an average redundancy of 10.46. $\lambda = 1.54178$ Å

Compound 6—A $0.38 \times 0.14 \times 0.05$ mm³ crystal of **6** was prepared for data collection coating with high viscosity microscope oil (Paratone-N, Hampton Research). The oil-coated crystal was placed on a MicroMesh mount (MiTeGen, Ithaca, NY) and transferred immediately to the diffractometer and data collected at room temperature using CuK α radiation ($\lambda = 1.54178$ Å) and a Bruker Platinum-135 CCD area detector. The crystal was monoclinic in space group $P2_1$ with unit cell dimensions $a = 9.7084(1)$ Å, $b = 10.6697(1)$ Å, $c = 11.7781(2)$ Å, and $\beta = 108.681(1)^\circ$. Corrections were applied for Lorentz, polarization, and absorption effects. The crystal was twinned and data for the major component were 96.5% complete to $67.53^\circ \theta$ (approximately 0.83 Å) with an average redundancy of 0.97.

In an attempt to find a non-tinned crystal of **6** a polymorph was discovered. A $0.773 \times 0.066 \times 0.056$ mm³ crystal of **6** (orthorhombic polymorph) was prepared for data collection coating with high viscosity microscope oil (Paratone-N, Hampton Research). The oil-coated crystal was placed on a MicroMesh mount (MiTeGen, Ithaca, NY) and transferred immediately to the cold stream (103°K) on the diffractometer. The crystal was orthorhombic in space group $P2_12_12_1$ with unit cell dimensions $a = 8.0735(9)$ Å, $b = 16.1265(17)$ Å, and $c = 37.756(4)$ Å. Corrections were applied for Lorentz, polarization, and absorption effects. The crystal was twinned and data for the major component were 99.3% complete to $25.31^\circ \theta$ (approximately 0.83 Å) with an average redundancy of 3.93.

Compound 8—A $0.638 \times 0.498 \times 0.385$ mm³ crystal of **8** was prepared for data collection coating with high viscosity microscope oil (Paratone-N, Hampton Research). The oil-coated crystal was placed on a MicroMesh mount (MiTeGen, Ithaca, NY) and transferred immediately to the cold stream (100°K) on the diffractometer. The crystal was monoclinic in space group $P2_1$ with unit cell dimensions $a = 10.5597(4)$ Å, $b = 10.4870(3)$ Å, $c = 12.5566(4)$ Å, and $\beta = 103.170(1)^\circ$. Corrections were applied for Lorentz, polarization, and absorption effects. Data were 95.8% complete to $25.00^\circ \theta$ (approximately 0.83 Å) with an average redundancy of 4.41.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by the NIH Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Drug Abuse, and the National Institute of Alcohol Abuse and Alcoholism, NIH, DHHS. We thank Noel Whittaker and Dr. John Lloyd (Mass Spectrometry Facility, NIDDK) for the ms data, and Drs. Klaus Gawrisch and Walter Teague (Laboratory of Membrane Biochemistry and Biophysics, NIAAA) for NMR spectroscopic data. The X-ray crystallographic work was supported by NIDA through an Interagency Agreement #Y1-DA1101 with the Naval Research Laboratory (NRL).

References

1. Kamano Y, Nogawa T, Yamashita A, Hayashi M, Inoue M, Draar P, Pettit GR. *J Nat Prod.* 2002; 65:1001–1005. [PubMed: 12141860]
2. Enomoto A, Mun-Chual Rho M-C, Komiyama K, Hayashi M. *J Nat Prod.* 2004; 67:2070–2072. [PubMed: 15620253]
3. Enomoto A, Mun-Chual Rho M-C, Fukami A, Hiraku O, Komiyama K, Hayashi M. *Biochem Biophys Res Commun.* 2004; 323:1096–1102. [PubMed: 15381112]
4. Hayashi M, Rho MC, Fukami A, Enomoto A, Nonaka S, Sekiguchi Y, Yanagisawa T, Yamashita A, Nogawa T, Kamano Y, Komiyama K. *J Pharmacol Exp Ther.* 2002; 303:104–109. [PubMed: 12235239]

5. Kino T, Boos TL, Sulima A, Siegel EM, Gold PW, Rice KC, Chrousos GP. *J Allergy Clinical Immunol.* 2007; 120:437–444. [PubMed: 17451794]
6. Vardanyan M, Melemedjian OK, Price TJ, Ossipov MH, Lai J, Roberts E, Boos TL, Deschamps JR, Jacobson AE, Rice KC, Porreca F. *Pain.* 2010; 151:257–265. [PubMed: 20599324]
7. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. *Neuroimmunomodulation.* 2005; 12:255–269. [PubMed: 16166805]
8. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. *Biochem J.* 2003; 374(1):1–20. [PubMed: 12773095]
9. Nishimoto N. *Curr Opin Rheumatol.* 2006; 18:277–281. [PubMed: 16582692]
10. Bruunsgaard H, Pedersen M, Pedersen BK. *Curr Opin Hematol.* 2001; 8:131–136. [PubMed: 11303144]
11. Kaneda N, Kuraishi T, Yamasaki K. *Chem Pharm Bull.* 1981; 29:257–259.
12. Xie JT, Wang H, Attele AS, Yuan CS. *Am J Chin Med.* 2000; 28:187–196. [PubMed: 10999437]
13. Pettit GR, Houghton LE, Knight JC, Bruschweiler F. *J Org Chem.* 1970; 35:2895–2898. [PubMed: 5450525]
14. Hoofst RWW, Straver LH, Spek AL. *J Appl Cryst.* 2008; 41:96–103. [PubMed: 19461838]
15. Spek, AL. *PLATON (v 1.15).* Utrecht University; Utrecht, The Netherlands: 2011.
16. Flack HD. *Acta Cryst.* 1983; A39:876–881.
17. Hashimoto T, Rathore H, Satoh D, Griffin JF, From AHL, Ahmed K, Fullerton DS, Hong G. *J Med Chem.* 1986; 29:997–1003. [PubMed: 3012087]
18. Pettit GR, Kamano Y, Bruschweiler F, Brown P. *J Org Chem.* 1971; 36:3736–3739. [PubMed: 5120710]
19. Meyer K. *Helv Chim Acta.* 1952; 35:2444–2469.
20. Murray RW, Singh M. *Org Synth, Coll.* 1998; 9:288.
21. Yang D, Wong M-K, Yip Y-C. *J Org Chem.* 1995; 60:3887–3889.
22. Krimen LI. *Org Synth, Coll.* 1988; 6:8–9.

(+)-20*R*,21*R*-epoxyresibufogenin-3-formate (**1**)

(-)-20*S*,21*S*-epoxyresibufogenin-3-formate (**2**)

Figure 1. Structure of (+)-20*R*,21*R*-epoxyresibufogenin-3-formate (**1**) and (-)-20*S*,21*S*-epoxyresibufogenin-3-formate (**2**) as determined by X-ray crystallography. Displacement ellipsoids are at the 50% level.

20*R*,21*R*-Epoxyresibufogenin (**4**)

(+)-20*R*,21*R*-epoxyresibufogenin 3-acetate (**6**)

(+)-20*R*,21*R*-epoxyresibufogenin 3-(4-bromobenzoate) (**8**)

Figure 2.

Structure of 20*R*,21*R*-epoxyresibufogenin (**4**), (+)-20*R*,21*R*-epoxyresibufogenin 3-acetate (**6**), and (+)-20*R*,21*R*-epoxyresibufogenin 3-(4-bromobenzoate) (**8**) as determined by X-ray crystallography. Displacement ellipsoids are at the 50% level.

Scheme 1. Synthesis of 20R,21R-epoxyresibufogenin-3-formate (1), 20S,21S-epoxyresibufogenin-3-formate (2), and 20R,21R-resibufogenin-3-acetate (6)^{a,1}

^aReagents and conditions: (a) Iron (III) acetylacetonate, H₂O₂, CH₃CN, 0 °C, 24–31%; (b) Ac₂O, pyridine, 24 h, rt, 76%; (c) HCO₂H, pyridine, rt.

Scheme 2. Improved synthesis of 20R,21R-epoxyresibufogenin-3-formate (1) and preparation of 20R,21R-epoxyresibufogenin 3-(4-bromobenzoate) (8)^a

^aReagents and conditions: (a) acetic formic anhydride, pyridine, 0–5 °C, 2h, 93%; (b) method A: dimethyldioxirane, acetone, CH₂Cl₂, rt, 2 days, 71%, method B: Oxone,²¹ NaHCO₃, CH₃CN, Na₂EDTA, trifluoroacetone, 5 °C, 1h, 56%; (c) DMAP, CH₂Cl₂, *p*-bromobenzoyl chloride, rt, 14 h.

Table 1Selected Observed and Reported ^1H NMR Chemical Shifts [CDCl_3 , δ_{H} (J , Hz)] of Compounds 1 and 2

	observed	lit. ¹	observed	lit. ¹
position	1 (300 MHz)	1 (500 MHz) ¹	2 (300 MHz)	2 (500 MHz) ¹
3a	5.24	5.24 brs	5.24 s	5.23 s
15a	3.57	3.57 s	3.46 s	3.45 s
16a	2.31	2.29	2.18	2.10
18	1.03	1.03 s	1.19 s	1.19 s
19	1.01s	1.00 s	1.03 s	1.02 s
21	5.30	5.30 s	5.41 s	5.40 s
22	7.93 (10.2, 1.2)	7.93 dd (10.9, 0.5)	7.69 d (9.9)	7.69 brd (7.3)
23	6.05 (10.5)	6.04 d (10.1)	6.07 d (9.9)	6.06 d (10.1)
1'	8.07	8.07	8.08	8.07

Table 2¹³C NMR (CDCl₃) Comparison of Observed and Reported Chemical Shifts of Compounds 1 and 2

carbon	observed	lit. ¹	observed	lit. ¹
	1 (125 MHz)	1 (125 MHz) ¹	2 (75 MHz)	2 (125 MHz) ¹
1	30.3	30.2	30.4	30.2
2	25.7	25.6	25.8	25.6
3	70.5	70.4	70.6	70.4
4	30.5	30.4	30.6	30.4
5	36.8	36.7	36.9	36.7
6	25.2	25.0	25.2	25.1
7	20.7	20.6	20.9, 20.8	20.7
8	33.3	33.2	33.3	33.1
9	39.5	39.4	39.7	39.5
10	35.4	35.3	35.5	35.3
11	20.8	20.6	20.9, 20.8	20.6
12	39.8	39.7	40.1	40.0
13	44.2	44.1	45.1	44.9
14	75.3	75.1	75.2	75.0
15	60.0	59.9	60.2	60.0
16	28.7	28.6	28.2	28.0
17	51.9	51.8	50.4	50.2
18	16.3	16.2	16.1	15.9
19	23.7	24.0	23.9	23.7
20	56.6	56.5	55.7	55.5
21	84.7	84.6	83.1	82.9
22	148.0	147.8	149.6	149.3
23	121.6	121.5	122.5	122.3
24	159.9	159.8	160.1	159.9
1'	160.8	160.7	160.9	160.7

Table 3Comparison of Observed and Reported IR (cm^{-1}) Data of 4 and 5

	observed	lit. ¹	observed	lit. ¹
4 (KBr)	4 (solid probe)	4 (KBr)¹	5 (solid probe)	5 (KBr)¹
3460		3465	3473	3475
	3060	3070	3079	3070
2934	2931	2937	2936	2933
2871	2864	2877	2876	2874
1743	1739	1744	1744	1739
1627	1626	1625	1628	1628
		1533		1534
1123		1123	1123	1120
1090	1088	1089	1089	1086
984	983	982	985	984
867	867	886	876	865
800	796	785	790	789
				782